Latest AKRO reports update at 2024-02-29: 2023 ∙ 2022 ∙ 2021

Akero Therapeutics AKRO

$ 19.66 -0.25%

Akero Therapeutics Financial Statements 2011-2024 | AKRO

Annual Financial Statements Akero Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	1.44 B	1.59 B	617 M	1 B	375 M	-	-	-	-	-	-	-	-
Shares	52.6 M	39 M	34.8 M	34 M	15.1 M	-	-	-	-	-	-	-	-
Historical Prices	27.3	40.7	17.7	30.4	21.8	-	-	-	-	-	-	-	-
Net Income	-152 M	-112 M	-101 M	-79.2 M	-43.8 M	-81.7 M	-	-	-	-	-	-	-
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-173 M	-115 M	-101 M	-80.2 M	-45.7 M	-13.8 M	-	-	-	-	-	-	-
Interest Expense	3.1 M	739 K	-	-	1.9 M	-67.9 M	-	-	-	-	-	-	-
EBITDA	-173 M	-115 M	-101 M	-80.1 M	-45.7 M	-13.8 M	-	-	-	-	-	-	-
Operating Expenses	-	-	-	80.2 M	45.7 M	-	-	-	-	-	-	-	-
General and Administrative Expenses	31.1 M	29.9 M	19.1 M	15.2 M	8.6 M	1.9 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Income Statement Akero Therapeutics

	2023-Q3	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	55.6 M	46.9 M	46.9 M	38.7 M	-	35 M	34.9 M	34.9 M	34.8 M	34.7 M	34.7 M	34 M	28.6 M	28.5 M	28.6 M	28 M	3.27 M	168 K	239 K	127 K	92.2 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-39.7 M	-25.8 M	-	-35.5 M	-27.4 M	-26 M	-	-24.3 M	-28.9 M	-15.1 M	-	-79.2 M	-79.2 M	-79.2 M	-	-43.8 M	-43.8 M	-43.8 M	-	-11.1 M	-8.67 M	-421 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-46.6 M	-28.8 M	-	-36.1 M	-	-26.1 M	-	-24.4 M	-29 M	-15.1 M	-	-21.5 M	-16.5 M	-12.4 M	-	-16.3 M	-7.61 M	-5.51 M	-	-1.73 M	-8.66 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	888 K	457 K	-	324 K	-	-	-	-	-	-	-	135 K	247 K	493 K	-	755 K	381 K	150 K	-	-9.42 M	-11 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-28.7 M	-	-36.1 M	-	-26 M	-	-24.3 M	-29 M	-15.1 M	-	-21.5 M	-16.5 M	-12.4 M	-	-16.3 M	-7.61 M	-5.51 M	-	-1.73 M	-8.66 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	7.98 M	6.97 M	-	11 M	-	5.54 M	-	4.88 M	4.99 M	4.53 M	-	4.16 M	3.42 M	3.59 M	-	2.42 M	1.65 M	1.45 M	-	474 K	242 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency